Washington, D.C. 20549






Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported):  December 19, 2016


Brainstorm Cell Therapeutics Inc.

(Exact name of registrant as specified in its charter)


Delaware 001-36641 20-7273918
(State or other jurisdiction of incorporation) (Commission File No.) (IRS Employer Identification No.)


3 University Plaza Drive, Suite 320  
Hackensack, NJ 07601
(Address of principal executive offices) (Zip Code)


(201) 488-0460

(Registrant’s telephone number, including area code)



(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 7.01  Regulation FD Disclosure.


On December 19, 2016, at 8:30 a.m. Eastern Time, Brainstorm Cell Therapeutics Inc. (the “Company”) will hold a conference call to provide an update to stockholders to discuss ongoing progress with NurOwn® in the treatment of amyotropic lateral sclerosis (ALS) and Company plans for 2017. Notice of this conference call was previously given on December 6, 2016 via press release, a copy of which is furnished as Exhibit 99.1 to this Form 8-K. 


This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.


Item 8.01  Other Events.


On December 19, 2016, the Company issued a press release providing a corporate update and announced its clinical development objectives for 2017. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.


Item 9.01Financial Statements and Exhibits.


(d) Exhibits.


Exhibit No. 



99.1   Press Release dated December 6, 2016
99.2   Press Release dated December 19, 2016







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: December 19, 2016 Brainstorm Cell Therapeutics Inc.



/s/ Chaim Lebovits

    Chaim Lebovits
  Chief Executive Officer and President